Scholars Central

Conference abstractPublished 2018

Selective kinase inhibitors for the treatment of CNS disorders

Authors: Jinhwa Lee

1ST Biotherapeutics Inc., South Korea

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The kinase inhibitors have been utilized for the treatment of cancers since the discovery of the first drug, Imatinib. To date, there are over 40 kinase inhibitors approved by the US FDA, with a majority of these being small molecules. Despite the rapid growing development of kinase inhibitors for cancer, currently none of these agents are approved for CNS (central nervous system) diseases, mainly due to issues associated with CNS drug discovery. Protein kinases have been identified as potential therapeutic targets in neuronal cells and microglia. Many studies have suggested important roles of protein kinases in neuronal toxicity and microglial activation. Parkinson’s disease (PD) is the second most common neurodegenerative disorder. There are 7-10 million PD patients worldwide. So far there is no disease modifying therapy known. -Synuclein and Lewy body pathology have been strongly implicated in PD and dementia with Lewy body. Abl (Abelson kinase, c-abl) is activated in various neurodegenerative conditions including AD, PD and ALS. Abl activation is sufficient to trigger neurodegeneration. Abl is activated by neuroinflammation, oxidative stress and mitochondrial dysfunction in neurons and microglia. Here the highlights of our drug discovery program toward the novel treatment of CNS disorders will be addressed along the line.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutical Sciences & Emerging Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Sciences & Emerging Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Jinhwa Lee”